Nanoemulsion-based nasal in situ gel of olanzapine
Oral delivery of olanzapine suffers from low oral bioavailability and there has been reports of metabolic side effects. This study aimed to prepare a nanoemulsion of olanzapine and incorporate it into an in situ gel for nasal delivery. Such nasal delivery of olanzapine could provide prolonged contac...
Uloženo v:
| Vydáno v: | Journal of excipients and food chemicals Ročník 14; číslo 1 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
International Pharmaceutical Excipients Council
01.03.2023
|
| ISSN: | 2150-2668 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Oral delivery of olanzapine suffers from low oral bioavailability and there has been reports of metabolic side effects. This study aimed to prepare a nanoemulsion of olanzapine and incorporate it into an in situ gel for nasal delivery. Such nasal delivery of olanzapine could provide prolonged contact time with the nasal mucosa and a potential enhanced action with lower side effects. Several formulations of nanoemulsions were prepared and characterized through the measurements of conductivity, transmittance, pH, viscosity, hydrodynamic diameter, polydispersity index, Zeta potential, entrapment efficiency, and release profiles. In addition, a pharmacodynamics study was conducted through animal studies. The selected formulation showed excellent nanoemulsion with a size in the nanometre range, a good polydispersity index with acceptable stability as indicated by the thermodynamic stability test. The cumulative percentage of olanzapine released from the nanoemulsion showed a good release profile. Pharmacodynamics study on rats using Paw test demonstrated a very clear enhancement in the anti psychotic efficacy of olanzapine in the following order: Nanoemulsion-based in situ gel (with HPMC) > nanoemulsion based in situ gel > nanoemulsion > solution. Interestingly, olanzapine from the nanoemulsion-based in situ gel showed comparable antipsychotic efficacy to haloperidol, when given intraperitoneally. Nanoemulsion based nasal in situ gel is a promising drug delivery system for olanzapine for achieving a targeted delivery. However, further investigations on olanzapine accumulation in the brain after such delivery are recommended. |
|---|---|
| AbstractList | Oral delivery of olanzapine suffers from low oral bioavailability and there has been reports of metabolic side effects. This study aimed to prepare a nanoemulsion of olanzapine and incorporate it into an in situ gel for nasal delivery. Such nasal delivery of olanzapine could provide prolonged contact time with the nasal mucosa and a potential enhanced action with lower side effects. Several formulations of nanoemulsions were prepared and characterized through the measurements of conductivity, transmittance, pH, viscosity, hydrodynamic diameter, polydispersity index, Zeta potential, entrapment efficiency, and release profiles. In addition, a pharmacodynamics study was conducted through animal studies. The selected formulation showed excellent nanoemulsion with a size in the nanometre range, a good polydispersity index with acceptable stability as indicated by the thermodynamic stability test. The cumulative percentage of olanzapine released from the nanoemulsion showed a good release profile. Pharmacodynamics study on rats using Paw test demonstrated a very clear enhancement in the anti psychotic efficacy of olanzapine in the following order: Nanoemulsion-based in situ gel (with HPMC) > nanoemulsion based in situ gel > nanoemulsion > solution. Interestingly, olanzapine from the nanoemulsion-based in situ gel showed comparable antipsychotic efficacy to haloperidol, when given intraperitoneally. Nanoemulsion based nasal in situ gel is a promising drug delivery system for olanzapine for achieving a targeted delivery. However, further investigations on olanzapine accumulation in the brain after such delivery are recommended. |
| Author | Zahraa H Ali Myasar Alkotaji |
| Author_xml | – sequence: 1 fullname: Zahraa H Ali – sequence: 2 fullname: Myasar Alkotaji |
| BookMark | eNotjc1KAzEURoMoWGvfIS8wkOQmmZmlFH8KxW50PdxMbkpKmpTJdKFP76CezQdn8Z0HdptLphu2UtKIRlnb3bNNrSexAL1qrVgx9Y650Pmaaiy5cVjJ84wVE4-Z1zhf-ZESL4GXhPkbLzHTI7sLmCpt_nfNPl-eP7Zvzf7wuts-7Rsvwc6NddIYYwm89EI7JcC1gKIdJYQ-ACmvLGnrtBUqGE8uaKOM7AN5YxAB1mz39-sLnobLFM84fQ0F4_ArynQccJrjmGhwozewRIL2XjsDjkbntIFu0Z0cNfwAwNtO2g |
| ContentType | Journal Article |
| DBID | DOA |
| DatabaseName | DOAJ Directory of Open Access Journals |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2150-2668 |
| ExternalDocumentID | oai_doaj_org_article_bcd5304bf4dd4b53becbb4538d5381c4 |
| GroupedDBID | --- 5VS A8Z ABDBF ACUHS ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV EBD ESTFP ESX GROUPED_DOAJ GX1 KQ8 MK0 M~E OK1 TUS |
| ID | FETCH-LOGICAL-d136t-6b15556e3d1d04b203b73a07c13f9f3e2d26e46b4602f5debf452519fed55aa33 |
| IEDL.DBID | DOA |
| IngestDate | Fri Oct 03 12:44:35 EDT 2025 |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d136t-6b15556e3d1d04b203b73a07c13f9f3e2d26e46b4602f5debf452519fed55aa33 |
| OpenAccessLink | https://doaj.org/article/bcd5304bf4dd4b53becbb4538d5381c4 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bcd5304bf4dd4b53becbb4538d5381c4 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Journal of excipients and food chemicals |
| PublicationYear | 2023 |
| Publisher | International Pharmaceutical Excipients Council |
| Publisher_xml | – name: International Pharmaceutical Excipients Council |
| SSID | ssj0000392760 |
| Score | 2.238512 |
| Snippet | Oral delivery of olanzapine suffers from low oral bioavailability and there has been reports of metabolic side effects. This study aimed to prepare a... |
| SourceID | doaj |
| SourceType | Open Website |
| Title | Nanoemulsion-based nasal in situ gel of olanzapine |
| URI | https://doaj.org/article/bcd5304bf4dd4b53becbb4538d5381c4 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals databaseCode: DOA dateStart: 20100101 customDbUrl: isFulltext: true eissn: 2150-2668 dateEnd: 20241231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0000392760 providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources databaseCode: M~E dateStart: 20100101 customDbUrl: isFulltext: true eissn: 2150-2668 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0000392760 providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELZQxcCCeAooIA-oUy0SvxKPgFoxQNWhoG5R_EKVSlo1CVIZ-O2ck0rtxsLiwcNZ_iz77rPP3yF054W1IlHAToRRhGvHSCp5RKxS2jNLE9O84L-_JKNROp2q8U6pr5AT1soDt8Dda2MFUO6QT2a5FgzG1JrDNoXuNDaNEihEPTtkqjmDwe0nQXZyR4i_8RjDI3S4CfXwQzvEMdpzxQnqjVut6HUfT7Zfn8o-7uHxVkV6fYoonHsL91nPw3UWCc7G4iIvweCswOWsqvGHm-OFx8BNi-98CdHiGXobDiZPz2RT4IDYmMmKSA3eXEjHbGxhijRiOmF5lJiYeeWZo5ZKx6XmMqIAqgMQRPhp6p0VIs8ZO0edYlG4C4SBRkSeG51TsAS2NPNp7CVwRJ0qZ-klegxIZMtWwyILqtJNB2CdbbDO_sL66j-MdNFBKNne5nFdo061qt0N2jdf1axc3TbLCO3rz-AXNI-omQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanoemulsion-based+nasal+in+situ+gel+of+olanzapine&rft.jtitle=Journal+of+excipients+and+food+chemicals&rft.au=Zahraa+H+Ali&rft.au=Myasar+Alkotaji&rft.date=2023-03-01&rft.pub=International+Pharmaceutical+Excipients+Council&rft.eissn=2150-2668&rft.volume=14&rft.issue=1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_bcd5304bf4dd4b53becbb4538d5381c4 |